Financial News Feed

Today VKTXW ranks # as BUY CANDIDATE.
Today VKTXW ranks # as BUY CANDIDATE.

VKTXW stock VKTXW

VKTXW stock
VKTXW

Using projections from 8 individual sell-side analysts polled by Zacks Research, Viking Therapeutics, Inc. (NASDAQ:VKTX) has a current quarter EPS consensus estimate of -0.09. Going back to the previo...

Read more

Both Viking Therapeutics Inc. (NASDAQ:VKTX) and Gritstone Oncology Inc. (NASDAQ:GRTS) are each other’s competitor in the Biotechnology industry. Thus the compare of their analyst recommendations, pr...

Read more

The stock of Viking Therapeutics, Inc. (NASDAQ:VKTX) is a huge mover today! The stock increased 7.32% or $0.58 during the last trading session, reaching $8.44....

Read more

Company shares of Viking Thera (VKTX) have seen the Rank Correlation Indicator climb higher over the past 3 trading days, suggesting that it could be nearing a turning point if the reading crosses the...

Read more

Today we are spotlighting shares of Viking Therapeutics, Inc. (NasdaqCM:VKTX) and looking at how the firm stacks up in terms of valuation by the numbers. One of the most important ratios to look at wh...

Read more

LIGAND PHARMACEUTICALS INC, 10% Owner, sold 262,881 shares of the Viking Therapeutics, Inc. (NASDAQ:VKTX) in an exchange that happened on September 25th. The stock was sold at an average price of $19....

Read more

Major market players are buzzing over Viking Therapeutics, Inc. (NASDAQ:VKTX) as their share price hit $7.72 at the end of the most recent trading session. Outstanding shares are common stock authoriz...

Read more

Taking a look at shares of Viking Therapeutics, Inc. (NASDAQ:VKTX), we can see that the average consensus target price based on contributing analysts is currently $23.63. Sell-side analysts often prov...

Read more

Viking Thera (VKTX) have climbed higher over the course of the past week revealing positive upward momentum for the shares. In taking a look at recent performance, we can see that shares have moved 2....

Read more

Viking Therapeutics (NASDAQ:VKTX) had its price target decreased by Raymond James from $43.00 to $40.00 in a report published on Thursday morning. Raymond James currently has a strong-buy rating on th...

Read more

William Blair reissued their outperform rating on shares of Viking Therapeutics (NASDAQ:VKTX) in a research report sent to investors on Thursday morning. Several other equities analysts have also rece...

Read more

Viking Therapeutics (NASDAQ:VKTX) had its target price reduced by Raymond James from $43.00 to $40.00 in a research report report published on Thursday morning. They currently have a strong-buy rating...

Read more

Viking Therapeutics, Inc. (NASDAQ:VKTX) currently has an Average Broker Rating of 1.25. This number is based on the 8 sell-side firms polled by Zacks. The ABR rank within the industry stands at 13. An...

Read more

Viking Therapeutics Inc (NASDAQ:VKTX) gapped down before the market opened on Friday after Raymond James lowered their price target on the stock from $43.00 to $40.00. The stock had previously closed ...

Read more

After looking for stocks with higher betas, we can see that Viking Therapeutics, Inc. (NASDAQ:VKTX) has a current beta of 2.75. The beta of a stock is typically used as a historical volatility indicat...

Read more

News Feed powered by

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank